S&P 500   4,230.07 (+0.01%)
DOW   32,937.84 (-0.20%)
QQQ   356.21 (+0.36%)
AAPL   172.15 (-0.15%)
MSFT   315.89 (+0.80%)
META   300.24 (-0.23%)
GOOGL   132.74 (+0.23%)
AMZN   125.85 (+0.91%)
TSLA   250.65 (+1.67%)
NVDA   435.48 (+0.07%)
NIO   8.63 (+0.23%)
BABA   83.86 (-0.80%)
AMD   100.58 (+0.50%)
T   14.53 (-1.69%)
F   12.00 (-0.58%)
MU   67.66 (-0.25%)
CGC   0.73 (+6.28%)
GE   108.03 (+0.25%)
DIS   79.20 (-0.43%)
AMC   7.85 (+0.00%)
PFE   33.80 (-0.29%)
PYPL   57.56 (+0.45%)
NFLX   375.68 (-0.28%)
S&P 500   4,230.07 (+0.01%)
DOW   32,937.84 (-0.20%)
QQQ   356.21 (+0.36%)
AAPL   172.15 (-0.15%)
MSFT   315.89 (+0.80%)
META   300.24 (-0.23%)
GOOGL   132.74 (+0.23%)
AMZN   125.85 (+0.91%)
TSLA   250.65 (+1.67%)
NVDA   435.48 (+0.07%)
NIO   8.63 (+0.23%)
BABA   83.86 (-0.80%)
AMD   100.58 (+0.50%)
T   14.53 (-1.69%)
F   12.00 (-0.58%)
MU   67.66 (-0.25%)
CGC   0.73 (+6.28%)
GE   108.03 (+0.25%)
DIS   79.20 (-0.43%)
AMC   7.85 (+0.00%)
PFE   33.80 (-0.29%)
PYPL   57.56 (+0.45%)
NFLX   375.68 (-0.28%)
S&P 500   4,230.07 (+0.01%)
DOW   32,937.84 (-0.20%)
QQQ   356.21 (+0.36%)
AAPL   172.15 (-0.15%)
MSFT   315.89 (+0.80%)
META   300.24 (-0.23%)
GOOGL   132.74 (+0.23%)
AMZN   125.85 (+0.91%)
TSLA   250.65 (+1.67%)
NVDA   435.48 (+0.07%)
NIO   8.63 (+0.23%)
BABA   83.86 (-0.80%)
AMD   100.58 (+0.50%)
T   14.53 (-1.69%)
F   12.00 (-0.58%)
MU   67.66 (-0.25%)
CGC   0.73 (+6.28%)
GE   108.03 (+0.25%)
DIS   79.20 (-0.43%)
AMC   7.85 (+0.00%)
PFE   33.80 (-0.29%)
PYPL   57.56 (+0.45%)
NFLX   375.68 (-0.28%)
S&P 500   4,230.07 (+0.01%)
DOW   32,937.84 (-0.20%)
QQQ   356.21 (+0.36%)
AAPL   172.15 (-0.15%)
MSFT   315.89 (+0.80%)
META   300.24 (-0.23%)
GOOGL   132.74 (+0.23%)
AMZN   125.85 (+0.91%)
TSLA   250.65 (+1.67%)
NVDA   435.48 (+0.07%)
NIO   8.63 (+0.23%)
BABA   83.86 (-0.80%)
AMD   100.58 (+0.50%)
T   14.53 (-1.69%)
F   12.00 (-0.58%)
MU   67.66 (-0.25%)
CGC   0.73 (+6.28%)
GE   108.03 (+0.25%)
DIS   79.20 (-0.43%)
AMC   7.85 (+0.00%)
PFE   33.80 (-0.29%)
PYPL   57.56 (+0.45%)
NFLX   375.68 (-0.28%)
NASDAQ:CDNA

CareDx (CDNA) Stock Forecast, Price & News

$6.62
-0.33 (-4.75%)
(As of 10:08 AM ET)
Compare
Today's Range
$6.62
$6.95
50-Day Range
$6.86
$11.26
52-Week Range
$6.22
$20.71
Volume
103,374 shs
Average Volume
1.02 million shs
Market Capitalization
$358.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.80

CareDx MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
98.6% Upside
$13.80 Price Target
Short Interest
Healthy
7.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.58mentions of CareDx in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$189,377 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.18) to ($2.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

534th out of 965 stocks

Medical Laboratories Industry

14th out of 25 stocks


CDNA stock logo

About CareDx (NASDAQ:CDNA) Stock

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CDNA Price History

CDNA Stock News Headlines

CareDx, Inc (NASDAQ:CDNA) Insider Sells $19,472.38 in Stock
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
CareDx's (CDNA) "Equal Weight" Rating Reaffirmed at Stephens
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Raymond James Upgrades Caredx (CDNA)
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
CareDx Reports Second Quarter 2023 Results
Craig-Hallum Reaffirms Their Hold Rating on CareDx (CDNA)
CareDx to Report Second Quarter 2023 Financial Results
CareDx: Regulatory Uncertainties Impacting Revenue
CareDx stock surges on the acquisition of MediGO
See More Headlines
Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

CDNA Company Calendar

Last Earnings
8/08/2023
Today
10/04/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDNA
Employees
727
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.80
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+98.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-76,610,000.00
Pretax Margin
-26.99%

Debt

Sales & Book Value

Annual Sales
$309.31 million
Book Value
$8.05 per share

Miscellaneous

Free Float
51,894,000
Market Cap
$376.47 million
Optionable
Optionable
Beta
1.02
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Reginald Seeto M.D. (Age 51)
    MBBS, Pres, CEO & Director
    Comp: $954.71k
  • Mr. Abhishek Jain (Age 46)
    CFO & Principal Accounting Officer
    Comp: $425.58k
  • Mr. Abraham Ronai Esq. (Age 49)
    Chief Admin. & Legal Officer and Sec.
    Comp: $566.49k
  • Dr. Peter Maag Ph.D. (Age 56)
    Exec. Director
    Comp: $43.23k
  • Ms. Sasha King M.B.A. (Age 37)
    Exec. Officer
    Comp: $343.34k
  • Mr. Alexander L. Johnson (Age 48)
    Pres of Patient and Testing Services
    Comp: $547.43k
  • Ms. Marica Grskovic Ph.D.
    Chief Operating Officer
  • Mr. Ian Cooney
    VP of Investor Relations
  • Dr. Mickey Y. Kim M.D.
    Sr. VP of Corp. Devel. & Head of Global Product
  • Mr. Jarrod Borkat
    Sr. VP and Head of Marketing & Portfolio Operations













CDNA Stock - Frequently Asked Questions

Should I buy or sell CareDx stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CDNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CDNA, but not buy additional shares or sell existing shares.
View CDNA analyst ratings
or view top-rated stocks.

What is CareDx's stock price forecast for 2023?

6 brokerages have issued 1-year target prices for CareDx's stock. Their CDNA share price forecasts range from $9.00 to $25.00. On average, they expect the company's stock price to reach $13.80 in the next twelve months. This suggests a possible upside of 98.6% from the stock's current price.
View analysts price targets for CDNA
or view top-rated stocks among Wall Street analysts.

How have CDNA shares performed in 2023?

CareDx's stock was trading at $11.41 at the start of the year. Since then, CDNA stock has decreased by 39.1% and is now trading at $6.95.
View the best growth stocks for 2023 here
.

Are investors shorting CareDx?

CareDx saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 3,900,000 shares, a decline of 5.8% from the August 31st total of 4,140,000 shares. Based on an average daily trading volume, of 835,900 shares, the days-to-cover ratio is presently 4.7 days.
View CareDx's Short Interest
.

When is CareDx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CDNA earnings forecast
.

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) announced its earnings results on Tuesday, August, 8th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.10. The business earned $70.30 million during the quarter, compared to the consensus estimate of $56.40 million. CareDx had a negative trailing twelve-month return on equity of 19.84% and a negative net margin of 27.15%.

What guidance has CareDx issued on next quarter's earnings?

CareDx issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $240.00 million-$260.00 million, compared to the consensus revenue estimate of $261.94 million.

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

How do I buy shares of CareDx?

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $6.95.

How much money does CareDx make?

CareDx (NASDAQ:CDNA) has a market capitalization of $376.47 million and generates $309.31 million in revenue each year. The company earns $-76,610,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does CareDx have?

The company employs 727 workers across the globe.

How can I contact CareDx?

CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.caredxinc.com. The company can be reached via phone at (415) 287-2300, via email at caroline.corner@westwicke.com, or via fax at 415-287-2450.

This page (NASDAQ:CDNA) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -